Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.
Everyday Health on MSN
MASH: Is semaglutide right for you?
Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.
Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...
Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...
Companion Spine, the French-American specialist in surgeon innovated spine implant surgery, announced that the U.S. Food and Drug Administration (the "FDA") has approved the DIAMtm Spinal ...
Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...
Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...
Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...
GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...
Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...
Inflammation likely plays a key role in T2D outcomes, and various anti-inflammatory treatments may improve both T2D and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback